Orifarm
Orifarm, officially known as Orifarm Group, is a prominent player in the pharmaceutical industry, headquartered in Denmark (DK). Founded in 1994, the company has established itself as a leader in the development, production, and distribution of generic medicines and parallel imports, primarily serving the European market. With a strong focus on quality and accessibility, Orifarm offers a diverse portfolio of products, including prescription medications and over-the-counter solutions. Their commitment to innovation and sustainability sets them apart in a competitive landscape. Over the years, Orifarm has achieved significant milestones, including expanding its operational reach across multiple European countries. The company is recognised for its dedication to improving patient access to essential medicines, solidifying its position as a trusted partner in the healthcare sector.
DitchCarbon Score
How does Orifarm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Orifarm's score of 64 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Orifarm's reported carbon emissions
In 2024, Orifarm reported total carbon emissions of approximately 3,178,000 kg CO2e for Scope 1 and about 7,300,000 kg CO2e for Scope 2 (market-based). This follows a 2023 report where Scope 1 emissions were around 4,420,000 kg CO2e and Scope 2 emissions were approximately 7,529,000 kg CO2e (market-based). The company has set ambitious targets to reduce its carbon footprint, aiming for a 30% reduction in both Scope 1 and Scope 2 emissions by 2025, using 2020 as the baseline. Looking towards the long term, Orifarm has committed to a significant reduction in absolute emissions, targeting a 54.6% decrease in Scope 1 and 2 emissions by 2033 from a 2023 baseline. Additionally, they aim for a 32.5% reduction in Scope 3 emissions within the same timeframe. The company is also focused on achieving exponential reductions in emissions as part of its long-term strategy towards 2050. Orifarm's climate commitments align with industry standards, reflecting a proactive approach to sustainability in the pharmaceuticals sector. The company is a member of the Science Based Targets initiative (SBTi), reinforcing its dedication to meeting climate goals consistent with limiting global warming to 1.5°C.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 605,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 395,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orifarm is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
